{
  "meta": {
    "title": "Ini_Cet_May_2025",
    "url": "https://brainandscalpel.vercel.app/ini-cet-may-2025-bf75ae65.html",
    "scrapedAt": "2025-11-30T07:36:06.861Z"
  },
  "questions": [
    {
      "id": 1,
      "choices": [
        {
          "id": 1,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 2, 3</span></p>"
        },
        {
          "id": 2,
          "text": "<p><span style=\"font-size:12.0pt;\">2, 3</span></p>"
        },
        {
          "id": 3,
          "text": "<p><span style=\"font-size:12.0pt;\">2, 3, 4</span></p>"
        },
        {
          "id": 4,
          "text": "<p><span style=\"font-size:12.0pt;\">3, 4</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following are correct statements about thalidomide?<br>\r\n 1) Has antimetabolite action?<br>\r\n 2) Used in type 2 lepra reaction?<br>\r\n 3) Has teratogenic effect?<br>\r\n 4) Used in refractory cases of multiple myeloma?\r\n</span></p>",
      "unique_key": "DT1332276",
      "question_audio": null,
      "question_video": null,
      "map_id": 1332276,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Thalidomide</strong> is an <em>immunomodulatory drug</em> that acts by inhibiting TNF-&alpha;, modulating T-cell function, and inhibiting angiogenesis.</p>\r\n<p>It has <strong>no antimetabolite action</strong> (Statement 1 ruled out).<br /> <strong>Uses:</strong></p>\r\n<ul>\r\n<li><strong>Type 2 lepra reaction (ENL):</strong> Reduces TNF-&alpha;, thereby controlling erythema nodosum leprosum.</li>\r\n<li><strong>Refractory multiple myeloma:</strong> Used as part of immunomodulatory drug (IMiD) regimens.</li>\r\n</ul>\r\n<p><strong>Teratogenicity:</strong> Classical adverse effect &rarr; <em>phocomelia</em> (limb defects) when used in pregnancy.</p>\r\n<p><strong>Excretion - </strong>Thalidomide and its metabolites are excreted in the urine, while the nonabsorbed portion of the drug is excreted unchanged in faeces.</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/FMGEMCQ/20250928b6204c07-643f-489e-87fc-e0138d7fcfd5.png\">",
      "correct_choice_id": 3,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2,
      "choices": [
        {
          "id": 11,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 3</span></p>"
        },
        {
          "id": 12,
          "text": "<p><span style=\"font-size:12.0pt;\">2, 3</span></p>"
        },
        {
          "id": 13,
          "text": "<p><span style=\"font-size:12.0pt;\">2</span></p>"
        },
        {
          "id": 14,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 4</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following statements are true about benzodiazepines and barbiturates?<br>\r\n 1) Flumazenil is an antidote for barbiturate <br> \r\n 2) They cause additive sedation with alcohol <br>\r\n 3) Thiopentone has short duration of action due to metabolism <br>\r\n 4) They cause inhibition of GABA chloride channels <br>\r\n\r\n</span></p>",
      "unique_key": "DT1332277",
      "question_audio": null,
      "question_video": null,
      "map_id": 1332277,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Benzodiazepines and barbiturates</strong> the two classes of agents, differ markedly in their potencies. Barbiturates act to enhance GABAA receptor function at low micromolar concentrations, while benzodiazepines are considerably more potent, binding with nanomolar affinity. Both benzodiazepines and barbiturates bind to allosteric sites on the GABA-A receptor pentamer and thereby enhance <strong>GABA-stimulated Cl-channel function</strong> <strong>(Statement 4 ruled out) </strong> &rarr; <strong>additive CNS depression</strong> with alcohol.</p>\r\n<p><strong>Thiopentone</strong> has a short duration <strong>not</strong> due to metabolism, but due to <strong>redistribution</strong> from brain to peripheral tissues <strong>(Statement 3 ruled out)</strong></p>\r\n<p><strong>(Thiopentone action)</strong></p>\r\n<p>Thiopentone IV &rarr; Rapid CNS penetration &rarr; Sleep (seconds) &rarr; Redistribution to muscle &amp; fat &rarr; Recovery</p>\r\n<p><strong>Flumazenil</strong> is a <strong>benzodiazepine antagonist</strong>, not effective in barbiturate poisoning <strong>(statement 1 Ruled out)</strong></p>",
      "correct_choice_id": 13,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3,
      "choices": [
        {
          "id": 21,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 3, 4</span></p>"
        },
        {
          "id": 22,
          "text": "<p><span style=\"font-size:12.0pt;\">2, 3, 4</span></p>"
        },
        {
          "id": 23,
          "text": "<p><span style=\"font-size:12.0pt;\">Only 4</span></p>"
        },
        {
          "id": 24,
          "text": "<p><span style=\"font-size:12.0pt;\">Only 3</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following are the uses of MgSO4?<br>\r\n 1) Increase renal perfusion<br>\r\n 2) Neuroprotection<br>\r\n 3) Prevention of seizures<br>\r\n 4) Prevention of abruption</span></p>",
      "unique_key": "DT1332278",
      "question_audio": null,
      "question_video": null,
      "map_id": 1332278,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Magnesium sulfate</strong> is a major drug in <strong>obstetrics</strong>. It is used in <strong>Prevention/treatment of seizures</strong> in preeclampsia &amp; eclampsia (Statement 3).</p>\n<p>It also provides <strong>Neuroprotection</strong> in preterm labour &rarr; reduces risk of cerebral palsy in neonates (Statement 2).</p>\n<p>It provides <strong>Prevention of abruption;</strong> by controlling severe hypertension and seizures, it indirectly reduces the risk of placental abruption (statement 4).</p>\n<p>It does not directly <strong>increase renal perfusion</strong> (<strong>Statement 1 is ruled out</strong>).</p>\n<p><strong>Table: MgSO<sub>4</sub>\n \n Uses in Obstetrics</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/FMGEMCQ/20250929dd335309-d0fa-40d6-b11b-67751729ff56.png\"><br>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/FMGEMCQ/202509294a21aeeb-17b2-4988-ba28-b926e1279552.png\">",
      "correct_choice_id": 22,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4,
      "choices": [
        {
          "id": 31,
          "text": "<p><span style=\"font-size:12.0pt;\">Refractory seizures due to pharmacodynamic resistance</span></p>"
        },
        {
          "id": 32,
          "text": "<p><span style=\"font-size:12.0pt;\">Carbamazepine toxicity due to drug interaction</span></p>"
        },
        {
          "id": 33,
          "text": "<p><span style=\"font-size:12.0pt;\">Erythromycin toxicity due to enzyme induction</span></p>"
        },
        {
          "id": 34,
          "text": "<p><span style=\"font-size:12.0pt;\">Decreased absorption of carbamazepine leading to subtherapeutic levels</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 28-year-old male with a history of generalized tonic-clonic seizures is on long-term carbamazepine therapy. He started taking erythromycin for a throat infection. Two days later, he presents with complaints of dizziness, diplopia, ataxia, and confusion. What is the most likely explanation for his symptoms? </span></p>",
      "unique_key": "DT1332279",
      "question_audio": null,
      "question_video": null,
      "map_id": 1332279,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Acute intoxication </strong>with carbamazepine can result in stupor or coma, hyperirritability, convulsions, and respiratory depression.<strong> During long-term therapy, </strong>the more frequent untoward effects of the drug include<strong> drowsiness, vertigo, ataxia, diplopia, and blurred vision.</strong></p>\n<p><strong>Carbamazepine</strong> is metabolized by <strong>CYP3A4</strong> while <strong>Erythromycin</strong> is a <strong>CYP3A4 inhibitor</strong> &rarr; reduces carbamazepine clearance &rarr; increased plasma levels &rarr; <strong>toxicity</strong> (neurological symptoms: diplopia, ataxia, confusion).</p>\n<p><strong>Drug Interaction-</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/FMGEMCQ/20250929312f8da5-d69b-4003-8cab-3ea88b4882f6.png\"><p><strong>Metabolism:</strong></p>\n<ul>\n<li>Phenobarbital, phenytoin, and valproate may<strong> increase the metabolism </strong>of carbamazepine by inducing <strong>CYP3A4.</strong></li>\n<li><strong>Inhibited by propoxyphene, erythromycin, cimetidine, fluoxetine, and isoniazid</strong></li>\n</ul>\n<p><strong>Explanation Of Other Options:</strong></p>\n<p><strong>Refractory seizures (Option A):</strong> Not due to resistance - patient has toxicity, not seizure recurrence.</p>\n<p><strong>Erythromycin toxicity (Option C):</strong> Erythromycin causes GI upset, not CNS toxicity from enzyme induction.</p>\n<p><strong>Decreased absorption (Option D):</strong> Wrong - erythromycin increases levels, not decreases.</p>\n<p><strong>Key Takeaways:</strong></p>\n<ul>\n<li>Carbamazepine = <strong>CYP3A4 substrate</strong>.</li>\n<li>Erythromycin = <strong>CYP3A4 inhibitor</strong>.</li>\n<li>Co-administration = <strong>carbamazepine toxicity</strong>.</li>\n</ul>",
      "correct_choice_id": 32,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5,
      "choices": [
        {
          "id": 41,
          "text": "<p><span style=\"font-size:12.0pt;\">To make the compound more permeable across membranes</span></p>"
        },
        {
          "id": 42,
          "text": "<p><span style=\"font-size:12.0pt;\">To extract functional proteins through oxidase/reductase reactions</span></p>"
        },
        {
          "id": 43,
          "text": "<p><span style=\"font-size:12.0pt;\">Introduce or expose functional groups for further metabolism</span></p>"
        },
        {
          "id": 44,
          "text": "<p><span style=\"font-size:12.0pt;\">To directly conjugate the compound and facilitate excretion</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">What is the main role of phase 1 in xenobiotic metabolism?</span></p>",
      "unique_key": "DT1332280",
      "question_audio": null,
      "question_video": null,
      "map_id": 1332280,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Xenobiotic-metabolizing enzymes</strong> have historically been categorized as</p>\n<ul>\n<li><strong>Phase 1 reactions, </strong>which include oxidation, reduction, and hydrolytic reactions</li>\n<li><strong>Phase 2 reactions, i</strong>n which enzymes catalyze conjugation of the substrate (the phase 1 product) with a second molecule</li>\n</ul>\n<p><strong>Phase 1 metabolism</strong> = \"functionalization reactions\" &rarr; oxidation, reduction, hydrolysis.</p>\n<p><strong>Purpose</strong>: <strong>introduce or expose functional groups</strong> (-OH, -NH<sub>2</sub>, -SH) on drug molecules. This makes the drug more <strong>polar</strong> and prepares it for <strong>Phase 2 conjugation</strong>.</p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/FMGEMCQ/2025092935c2fcd7-aff2-4178-8de5-c3d21c40854a.png\"><br>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/FMGEMCQ/20250929f452cbf5-02c2-4931-baa3-2961ffe5d72a.png\">\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>More permeable (Option A):</strong> Wrong - Phase 1 makes drugs more polar, not more permeable.</p>\n<p><strong>Extract proteins (Option B):</strong> Wrong - enzymes (CYP450, oxidases) modify drugs, not proteins.</p>\n<p><strong>Direct conjugation (Option D):</strong> That is <strong>Phase 2</strong> metabolism.</p>",
      "correct_choice_id": 43,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6,
      "choices": [
        {
          "id": 51,
          "text": "<p><span style=\"font-size:12.0pt;\">Imipramine inhibits diphenhydramine's action</span></p>"
        },
        {
          "id": 52,
          "text": "<p><span style=\"font-size:12.0pt;\">Diphenhydramine inhibits imipramine's action</span></p>"
        },
        {
          "id": 53,
          "text": "<p><span style=\"font-size:12.0pt;\">Both block muscarinic receptors</span></p>"
        },
        {
          "id": 54,
          "text": "<p><span style=\"font-size:12.0pt;\">Both are norepinephrine reuptake inhibitors</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following statements is true regarding the pharmacological relationship between imipramine and diphenhydramine?</span></p>",
      "unique_key": "DT1332281",
      "question_audio": null,
      "question_video": null,
      "map_id": 1332281,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Imipramine</strong> (a tricyclic antidepressant) blocks <strong>muscarinic (M) receptors</strong> as a notable adverse effect (anticholinergic): dry mouth, blurred vision, constipation, urinary retention, tachycardia. It is also a potent inhibitor of norepinephrine and serotonin reuptake (primary antidepressant action).<br /> <strong>Diphenhydramine</strong> (a first-generation H<sub>1 </sub> antihistamine) <em>also</em> has significant antimuscarinic activity - this causes its characteristic sedation and anticholinergic side effects.</p>\n<p>Therefore, the <strong>shared pharmacologic action</strong> between these two drugs is <strong>muscarinic receptor blockade</strong></p>\n<p><strong>Diphenhydramine is not a NE-reuptake inhibitor</strong>, and neither drug \"inhibits the other's action\" pharmacologically in the way the stem suggests. <strong>(Options A, B, D Ruled Out)</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/FMGEMCQ/20250925cd6b8188-aed1-48ca-a1cc-618d6da9aee6.png\">",
      "correct_choice_id": 53,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7,
      "choices": [
        {
          "id": 61,
          "text": "<p><span style=\"font-size:12.0pt;\">D<sub>1</sub> agonism</span></p>"
        },
        {
          "id": 62,
          "text": "<p><span style=\"font-size:12.0pt;\">D<sub>2</sub> antagonism</span></p>"
        },
        {
          "id": 63,
          "text": "<p><span style=\"font-size:12.0pt;\">&alpha; antagonism</span></p>"
        },
        {
          "id": 64,
          "text": "<p><span style=\"font-size:12.0pt;\">Muscarinic antagonism</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 62-year-old male with a history of coronary heart disease (CHD) and renal failure was admitted to the ICU with elevated blood pressure of 190/110 mmHg and declining urine output. The intensivist administers fenoldopam intravenously. How does this drug help in improving renal function in this patient?</span></p>",
      "unique_key": "DT1332282",
      "question_audio": null,
      "question_video": null,
      "map_id": 1332282,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Fenoldopam</strong> is a selective <strong>D<sub>1</sub>-dopamine receptor agonist</strong> (peripheral type) used by IV infusion in hypertensive emergencies.</p>\r\n<p><strong>D<sub>1</sub> receptors</strong> are located on renal (and mesenteric/coronary) vascular smooth muscle. Activation of D<sub>1</sub> &rarr; <strong>Gs coupling &rarr; &uarr; cAMP &rarr; vasodilation</strong> of renal arterioles &rarr; <strong>increased renal blood flow, natriuresis</strong>, and improved urine output.</p>\r\n<p>Fenoldopam lowers systemic BP and preferentially increases renal perfusion; hence, it can improve renal function in acute hypertensive renal compromise.</p>\r\n<p><strong>Explanation Of Other Options:</strong></p>\r\n<p><strong>D<sub>2</sub> antagonism (Option B):</strong> D<sub>2</sub> blockade affects presynaptic dopamine/adrenergic neurotransmission, not the primary renal vasodilatory mechanism.</p>\r\n<p><strong> &alpha; antagonism (Option C):</strong> &alpha;-blockade causes vasodilation generally but fenoldopam's specific renal benefit is D<sub>1</sub>-mediated.</p>\r\n<p><strong>Muscarinic antagonism (Option D):</strong> Not relevant to fenoldopam's renal effects.</p>",
      "correct_choice_id": 61,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8,
      "choices": [
        {
          "id": 71,
          "text": "<p><span style=\"font-size:12.0pt;\">2, 3</span></p>"
        },
        {
          "id": 72,
          "text": "<p><span style=\"font-size:12.0pt;\">2, 3, 4</span></p>"
        },
        {
          "id": 73,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 4</span></p>"
        },
        {
          "id": 74,
          "text": "<p><span style=\"font-size:12.0pt;\">3, 4</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is true regarding bempedoic acid?<br>\r\n1.\tIt is a non-competitive inhibitor of ATP-citrate lyase<br>\r\n2.\tIt is a dicarboxylic acid<br>\r\n3.\tIt inhibits de novo cholesterol synthesis in hepatocytes<br>\r\n4.\tIt can be used concomitantly with statins\r\n</span></p>",
      "unique_key": "DT1332283",
      "question_audio": null,
      "question_video": null,
      "map_id": 1332283,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Bempedoic acid </strong>is chemically an <strong>&alpha;, omega-dicarboxylic acid</strong> (a fatty-acid-like molecule).</p>\r\n<p><strong>Mechanism:</strong> It is a <strong>prodrug</strong> that is activated in the liver to its CoA thioester; the active form <strong>Competitively</strong> <strong>inhibits ATP-citrate lyase (ACL) (Statement 1 ruled out)</strong> - an enzyme upstream of HMG-CoA reductase. Thereby <strong>reducing de novo cholesterol synthesis</strong> in hepatocytes and lowering LDL-C.</p>\r\n<p><strong>Clinical use / combination:</strong> Bempedoic acid is indicated as an adjunct to statins (or for statin-intolerant patients) and <strong>can be combined with statins</strong> - but note important pharmacokinetic interactions (it can increase statin exposure modestly, especially simvastatin/pravastatin), so monitoring and dose adjustments may be needed.</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/FMGEMCQ/20250929fc1b1fd3-2f8b-43a8-80f2-4e5cfca0ae1b.png\">",
      "correct_choice_id": 72,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9,
      "choices": [
        {
          "id": 81,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 2 and 3 </span></p>"
        },
        {
          "id": 82,
          "text": "<p><span style=\"font-size:12.0pt;\">Only 1 </span></p>"
        },
        {
          "id": 83,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 3 and 4 </span></p>"
        },
        {
          "id": 84,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 2, 3 and 4 </span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which pharmacokinetic parameters are used to determine the loading dose of an orally administered drug?<br>\r\n1.\tVolume of distribution (Vd) <br>\r\n2.\tHalf-life<br>\r\n3.\tPlasma concentration <br>\r\n4.\tBioavailability\r\n\r\n</span></p>",
      "unique_key": "DT1332284",
      "question_audio": null,
      "question_video": null,
      "map_id": 1332284,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Loading dose (LD)</strong> = (Desired steady-state plasma concentration &times; Vd) &divide; Bioavailability.</p>\r\n<p><strong>Half-life</strong> determines maintenance dosing frequency and time to steady state, but it is <strong>not</strong> a direct component of the loading dose equation <strong>(Statement 2 ruled out)</strong><br /> For <strong>oral drugs</strong>, bioavailability (F) must be accounted for because oral dosing is reduced by first-pass extraction and incomplete absorption.</p>\r\n<p><strong>Formula (practical):</strong></p>\r\n<p> LD (oral) = (C_target &times; Vd) / F</p>\r\n<p>Where:</p>\r\n<p>C_target = desired plasma concentration (therapeutic target)</p>\r\n<p>Vd = volume of distribution</p>\r\n<p>F = fraction absorbed (bioavailability)</p>",
      "correct_choice_id": 83,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10,
      "choices": [
        {
          "id": 91,
          "text": "<p><span style=\"font-size:12.0pt;\">Acetaminophen (paracetamol)</span></p>"
        },
        {
          "id": 92,
          "text": "<p><span style=\"font-size:12.0pt;\">Amoxicillin-clavulanic acid</span></p>"
        },
        {
          "id": 93,
          "text": "<p><span style=\"font-size:12.0pt;\">Isoniazid</span></p>"
        },
        {
          "id": 94,
          "text": "<p><span style=\"font-size:12.0pt;\">Estrogen + androgen</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which drug is classically associated with cholestasis without significant portal inflammation?\r\n</span></p>",
      "unique_key": "DT1332285",
      "question_audio": null,
      "question_video": null,
      "map_id": 1332285,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Drug-induced liver injury (DILI)</strong> may present as primarily <strong>hepatocellular</strong>, <strong>cholestatic</strong>, or <strong>mixed</strong> patterns. <strong>Estrogens and certain anabolic androgens</strong> characteristically cause <strong>cholestasis</strong> - historically described as \"bland cholestasis,\" where there is canalicular cholestasis with <strong>relative absence of marked portal inflammatory infiltrates</strong>. This presents clinically with pruritus and cholestatic LFT pattern (&uarr; alkaline phosphatase, &uarr; bilirubin).</p>\r\n<p><strong>Acetaminophen</strong> &rarr; classic <strong>Centro-lobular hepatocellular necrosis</strong> (hepatocellular injury) <strong>(Option A ruled out)</strong></p>\r\n<p><strong>Amoxicillin-clavulanic acid</strong> &rarr; frequently <strong>cholestatic hepatitis</strong> but often accompanied by inflammatory features and bile-duct injury (immune-mediated cholestatic hepatitis) <strong>(Option B ruled out)</strong></p>\r\n<p><strong>Isoniazid</strong> &rarr; primarily <strong>hepatocellular injury</strong> (hepatitis) <strong>(Option C ruled out)</strong></p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/FMGEMCQ/20250929a75231d7-2b8b-43b9-82b8-e6ce079a9bf1.png\">",
      "correct_choice_id": 94,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11,
      "choices": [
        {
          "id": 101,
          "text": "<p><span style=\"font-size:12.0pt;\">Prevent premature LH surge during controlled ovarian stimulation (IVF)</span></p>"
        },
        {
          "id": 102,
          "text": "<p><span style=\"font-size:12.0pt;\">Advanced prostate cancer</span></p>"
        },
        {
          "id": 103,
          "text": "<p><span style=\"font-size:12.0pt;\">Treatment of hypogonadism</span></p>"
        },
        {
          "id": 104,
          "text": "<p><span style=\"font-size:12.0pt;\">Endometriosis</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is NOT an indication for a GnRH antagonist?\r\n</span></p>",
      "unique_key": "DT1332286",
      "question_audio": null,
      "question_video": null,
      "map_id": 1332286,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>GnRH antagonists</strong> (e.g., cetrorelix, ganirelix, and oral elagolix/relugolix in some uses; degarelix is used in prostate cancer) <strong>suppress gonadotropin release</strong> promptly by blocking GnRH receptors- leading to reduced LH/FSH and sex steroid production.<br /> <strong>Indications include:</strong></p>\r\n<ul>\r\n<li><strong>Prevention of premature LH surge (Option A)</strong> during controlled ovarian hyperstimulation (short course antagonists are widely used in IVF cycles).</li>\r\n<li><strong>Advanced prostate cancer (Option C):</strong> GnRH antagonists (degarelix) lower testosterone quickly without initial flare seen with agonists.</li>\r\n<li><strong>Endometriosis / uterine fibroids (Option D):</strong> GnRH analogues (agonists and some antagonists like elagolix) are used to suppress estrogen production and reduce disease activity.</li>\r\n</ul>\r\n<p><strong>Hypogonadism</strong> is a condition of <strong>low sex steroids</strong> - treating it requires <em>replacement</em> (testosterone or estrogen), not further suppression. Thus GnRH antagonists (which suppress gonadal function) are contraindicated for treating hypogonadism.</p>\r\n<p><strong>Key takeaways:</strong></p>\r\n<p>GnRH antagonists = agents to <strong>suppress</strong> gonadal steroid production - used when suppression is desired (IVF control, prostate cancer, endometriosis), never to <em>treat</em> hypogonadism.</p>",
      "correct_choice_id": 103,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 12,
      "choices": [
        {
          "id": 111,
          "text": "<p><span style=\"font-size:12.0pt;\">A-3, B-1, C-2, D-4 </span></p>"
        },
        {
          "id": 112,
          "text": "<p><span style=\"font-size:12.0pt;\">A-4, B-1, C-3, D-2 </span></p>"
        },
        {
          "id": 113,
          "text": "<p><span style=\"font-size:12.0pt;\">A-2, B-1, C-4, D-3 </span></p>"
        },
        {
          "id": 114,
          "text": "<p><span style=\"font-size:12.0pt;\">A-2, B-4, C-1, D-3</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Match the following drugs with their respective schedules:<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/FMGEMCQ/202509297aab8afa-f300-4a89-bd21-375e2466babe.png\"></span></p>",
      "unique_key": "DT1332287",
      "question_audio": null,
      "question_video": null,
      "map_id": 1332287,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>The <strong>Drugs &amp; Cosmetics Rules (India)</strong> classify drugs into multiple schedules with different dispensing and labelling rules:</p>\r\n<ul>\r\n<li><strong>Schedule H</strong>: prescription drugs that require an RMP prescription (many vaccines are included here).</li>\r\n<li><strong>Schedule G</strong>: drugs requiring the caution statement (e.g., insulin preparations historically listed under G).</li>\r\n<li><strong>Schedule X</strong>: highly restricted drugs (narcotics/psychotropics) - <strong>morphine</strong> is classically under tighter control (Schedule X / controlled drug lists/NDPS overlap).</li>\r\n<li><strong>Schedule Z</strong>: listings related to veterinary medicines / approved veterinary products (veterinary drugs).</li>\r\n</ul>\r\n<p><strong>Reference:</strong> Indian Drugs &amp; Cosmetics Rules Act (Schedules)</p>",
      "correct_choice_id": 114,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13,
      "choices": [
        {
          "id": 121,
          "text": "<p><span style=\"font-size:12.0pt;\">1 and 2 </span></p>"
        },
        {
          "id": 122,
          "text": "<p><span style=\"font-size:12.0pt;\">2 and 3 </span></p>"
        },
        {
          "id": 123,
          "text": "<p><span style=\"font-size:12.0pt;\">3 and 4 </span></p>"
        },
        {
          "id": 124,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 2, and 4 </span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following statements regarding cross tolerance and reverse tolerance is/are correct?<br> \r\n1.\tCross tolerance can occur between morphine and fentanyl due to their action on Î¼-opioid receptors.<br> \r\n2.\tReverse tolerance is seen with chronic use of cocaine, leading to increased susceptibility to seizures.<br>\r\n3.\tCross tolerance is a form of pharmacokinetic tolerance only.<br>\r\n4.\tReverse tolerance is typically associated with enzyme induction.\r\n\r\n</span></p>",
      "unique_key": "DT1332288",
      "question_audio": null,
      "question_video": null,
      "map_id": 1332288,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Cross-tolerance:</strong> When two drugs act at the same receptor system (e.g., &mu;-opioid receptor), tolerance to one (morphine) frequently confers cross-tolerance to another (fentanyl). This is typically <strong>pharmacodynamic</strong> (receptor desensitization/down-regulation), though pharmacokinetic mechanisms can also play a role in some cases. <strong>Statement 1 is true.</strong></p>\r\n<p><strong>Reverse tolerance (sensitization):</strong> Some drugs, notably <strong>psychostimulants</strong> like cocaine and amphetamines, may produce <strong>sensitization (reverse tolerance)</strong> with repeated exposure - i.e., an increased response (e.g., enhanced locomotor activation or greater seizure propensity) to the same dose over time. Thus <strong>Statement 2 is correct</strong> in principle (chronic stimulant exposure can produce sensitization and sometimes increased seizure susceptibility).</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/FMGEMCQ/20250929398710c1-2243-4791-bd3a-5ef0254d18d7.png\">\r\n<p><strong>Explanation Of Other Options:</strong></p>\r\n<p><strong>Cross tolerance is a form of pharmacokinetic tolerance only (Statement 3):</strong> False - cross-tolerance is commonly <strong>pharmacodynamic</strong> (receptor level) and not limited to pharmacokinetic changes.</p>\r\n<p><strong>Reverse tolerance typically associated with enzyme induction (Statement 4):</strong> False- enzyme induction causes increased metabolism and <strong>tolerance</strong>, not <strong>reverse tolerance</strong>; reverse tolerance arises from sensitization (neuronal/behavioural changes), not enzyme induction.</p>",
      "correct_choice_id": 121,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}